Nasdaq · CIK 0002020932
AGMB AgomAb Therapeutics NV
Insider trading from SEC Form 4. Last filing 4 d ago. Close $9.08 on Oct 9, 2026, +6% from the 52-week low and -49% from the high.
AgomAb Therapeutics NV (AGMB) has 6 SEC Form 4 filings on file from 5 insiders, the latest filed on Oct 9, 2026. In the last 90 days insiders made 4 open-market buys worth $311k and 0 open-market sells worth $0, net +$311k.
4 open-market trades have been scored at AGMB. The newest: David R Epstein (director) bought $45k of stock on Oct 8, 2026, filed Oct 9, 2026, scored 51 (moderate). The largest of the 4 shown: Tim Jasper Knotnerus (Chief Executive Officer) bought $94k on Oct 5, 2026, scored 60 (notable). 3 insiders bought within 14 days of each other around Oct 8, 2026.
AGMB closed at $9.08 on Oct 9, 2026, 6% above its 52-week low and 49% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AgomAb Therapeutics NV, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | David R Epstein director buy | $45k 5,000 shares | +50% | - | |
| 47Moderate | David R Epstein director buy | $86k 10,000 shares | - | - | |
| 54Moderate | Pierre Thadee Victor Kemula Chief Financial Officer buy | $86k 10,000 shares | - | - | |
| 60Notable | Tim Jasper Knotnerus Chief Executive Officer buy | $94k 11,000 shares | +102% | - |
Transactions
Every row filed, 10 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | David R Epstein director | POpen-market purchase Common shares | +5,000 | $8.90 | $45k | 15,000 | 4 d ago |
| Oct 6, 2026 | Pierre Thadee Victor Kemula Chief Financial Officer | POpen-market purchase Common shares | +3,000 | $8.67 | $26k | 3,000 | 6 d ago |
| Oct 5, 2026 | David R Epstein director | POpen-market purchase Common shares | +5,000 | $8.57 | $43k | 5,000 | 6 d ago |
| Oct 5, 2026 | Tim Jasper Knotnerus Chief Executive Officer | POpen-market purchase Common shares | +6,000 | $8.48 | $51k | 16,823 | 6 d ago |
| Oct 6, 2026 | David R Epstein director | POpen-market purchase Common shares | +5,000 | $8.70 | $44k | 10,000 | 6 d ago |
| Oct 6, 2026 | Pierre Thadee Victor Kemula Chief Financial Officer | POpen-market purchase Common shares | +5,000 | $8.57 | $43k | 8,000 | 6 d ago |
| Oct 6, 2026 | Tim Jasper Knotnerus Chief Executive Officer | POpen-market purchase Common shares | +5,000 | $8.70 | $44k | 21,823 | 6 d ago |
| Oct 6, 2026 | Pierre Thadee Victor Kemula Chief Financial Officer | POpen-market purchase Common shares | +2,000 | $8.54 | $17k | 10,000 | 6 d ago |
| Sep 11, 2026 | Naimish Patel director | AGrant or award Stock Option (Right to Buy)derivative | +56,328 | $0.00 | $0 | 56,328 | 28 d ago |
| Sep 11, 2026 | Marino Garcia director | AGrant or award Stock Option (Right to Buy)derivative | +57,482 | $0.00 | $0 | 57,482 | 28 d ago |
Insiders
Everyone who has filed a Form 4 here.
- David R Epsteindirector
- Marino Garciaceo, president, officer, director
- Pierre Thadee Victor KemulaChief Financial Officer
- Tim Jasper KnotnerusChief Executive Officer
- Naimish Patelofficer, director
Questions about AGMB
Answered from the filings on this page, as of the latest one.
Are insiders buying AGMB?
As of Oct 9, 2026, SEC Form 4 filings show 4 open-market buys worth $311k by 3 insiders and 0 open-market sells worth $0 by 0 insiders at AgomAb Therapeutics NV in the last 90 days, net +$311k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade AGMB on the open market?
David R Epstein (director) bought $45k of AGMB on Oct 8, 2026 and filed the Form 4 on Oct 9, 2026. InsiderTell scored 51 (moderate), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at AgomAb Therapeutics NV?
5 people have filed a Form 4 at AgomAb Therapeutics NV, among them David R Epstein (director), Marino Garcia (CEO, president and director), Pierre Thadee Victor Kemula (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.